Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) was downgraded by equities researchers at Guggenheim from a "buy" rating to a "neutral" rating in a note issued to investors on Friday, Marketbeat.com reports.
Other analysts have also issued reports about the company. William Blair restated an "outperform" rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Stifel Nicolaus cut shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and lowered their price objective for the company from $6.00 to $2.00 in a research report on Friday. Bank of America reduced their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Finally, HC Wainwright dropped their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Neumora Therapeutics presently has a consensus rating of "Hold" and an average price target of $10.14.
Check Out Our Latest Research Report on Neumora Therapeutics
Neumora Therapeutics Stock Up 6.7 %
NASDAQ:NMRA traded up $0.09 on Friday, reaching $1.43. The stock had a trading volume of 1,227,622 shares, compared to its average volume of 1,422,371. The company has a market capitalization of $231.63 million, a P/E ratio of -0.76 and a beta of 2.59. Neumora Therapeutics has a 1-year low of $1.26 and a 1-year high of $18.61. The stock has a fifty day moving average price of $2.24 and a 200-day moving average price of $8.52.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. Sell-side analysts predict that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.
Institutional Trading of Neumora Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Windmill Hill Asset Management Ltd boosted its position in shares of Neumora Therapeutics by 299.6% in the 4th quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company's stock worth $1,106,000 after purchasing an additional 78,252 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at about $770,000. Wexford Capital LP boosted its holdings in Neumora Therapeutics by 15.7% during the fourth quarter. Wexford Capital LP now owns 252,122 shares of the company's stock worth $2,672,000 after buying an additional 34,243 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Neumora Therapeutics during the 4th quarter worth about $364,000. Finally, Stempoint Capital LP bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $4,538,000. Institutional investors and hedge funds own 47.65% of the company's stock.
Neumora Therapeutics Company Profile
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading

Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.